Insilico Medicine and Qilu Pharmaceutical Sign Nearly $120 Million Drug Development Deal
I'm PortAI, I can summarize articles.
Insilico Medicine and Qilu Pharmaceutical Group have entered a strategic partnership worth nearly $120 million to develop small molecule inhibitors for cardiometabolic diseases. Insilico will utilize its Pharma.AI platform for molecule design, while Qilu will manage development and commercialization. The agreement includes milestone payments and royalties based on net sales, aiming to enhance innovative therapy development through AI.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments